Quinazoline Tyrosine Kinase Inhibitors With Irreversible Cysteine Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing tyrosine kinase inhibitors (TKIs) suffer from drug resistance and reversible inhibition, leading to ineffective treatment of diseases caused by tyrosine kinase overexpression, such as cancer.
Innovation Solution
Development of a quinazoline derivative TKI that irreversibly inhibits tyrosine kinase activity by forming a covalent bond with the cysteine residue in the ATP binding domain, using a functional group containing XCH2(CH2)nC=O to bond with the sulfhydryl group through a nucleophilic reaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of operation
If first generation TKIs (gefitinib, erlotinib) are used for reversible inhibition, then the drugs can be easily administered and have good initial curative effect, but they cause drug resistance and the efficacy is not strong and durable
Solution Approach 1:
The patent changes the inhibition mechanism parameter from reversible (hydrogen bonding) to irreversible (covalent bonding) by introducing a functional group containing XCH2(CH2)nC=O that forms a covalent bond with the sulfhydryl group of cysteine residue, thereby resolving the contradiction between ease of administration and durability of efficacy
Solution Approach 2:
The patent creates a composite molecular structure combining the quinazoline core (for ATP binding pocket recognition) with the functional group containing XCH2(CH2)nC=O (for covalent bonding to cysteine), achieving both high affinity and irreversible inhibition to overcome drug resistance
2Adaptability or versatility
If first generation TKIs are used for reversible inhibition, then the drugs have broad applicability, but the selectivity is not good enough and drug resistance occurs
Solution Approach 1:
The patent applies local quality by making different parts of the molecule perform different functions: the quinazoline core provides broad applicability through ATP binding pocket recognition, while the localized functional group XCH2(CH2)nC=O provides high selectivity through specific covalent bonding to the cysteine residue in the ATP binding domain
3Ease of manufacture
If reversible inhibition mechanism is used, then the drugs can be easily designed and synthesized, but the efficacy is not strong and durable enough
Solution Approach 1:
The patent segments the drug molecule into two functional parts: a quinazoline core structure (for ease of design and ATP binding) and a functional group containing XCH2(CH2)nC=O (for irreversible inhibition). This segmentation allows maintaining ease of manufacture while achieving strong and durable efficacy through covalent bonding
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The TKI effectively and irreversibly inhibits tyrosine kinase, offering improved treatment efficacy and overcoming drug resistance, as demonstrated by reduced tumor cell proliferation compared to gefitinib.
Implementation Method 1
The functional group tends to bond to a naked sulfhydryl group of a cysteine near an ATP binding domain of a tyrosine kinase through a nucleophilic reaction to form a covalent bond
Data Source
AI summary
The present disclosure provides a tyrosine kinase inhibitor having the general formula (I).R1 is C1-C6 alkyl, alkenyl, substituted alkenyl, alkynyl, substituted alkynyl, phenyl, mono-substituted phenyl, poly-substituted phenyl, trifluoromethyl, 2,2,2-trifluoroethyl, CH3O(CH2)n-,R being methyl, ethyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl, cyclopropyl, acetyl or acryloyl, and n being an integer from 1 to 6. R2 and R3 are respectively halogen, hydrogen, amino, substituted amino, cyano, hydroxyl, sulfonic acid group, sulfonamide, trifluoromethyl, 2,2,2-trifluoroethyl, methyl, methoxy or ethynyl. R2 and R3 are in an ortho, para or meta position. Y is NH, O, S or Z—N, where Z is methyl, ethyl, isopropyl, trifluoromethyl, 2,2,2-trifluoroethyl or cyclopropyl. X is Cl, Br or F.